Alexion Pharmaceuticals

ALXN

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease.

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announces achievement of milestone using J-Brain Cargo® for neurodegenerative disease in research collaboration with Alexion.

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

HYOGO, Japan--(BUSINESS WIRE)--JCR announced an agreement with Alexion for the development of novel oligonucleotide therapeutics to support targeted delivery using J-Brain Cargo®.